Novan, Inc. (USD) Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Novan, Inc. (USD) Passive

4020 Stirrup Creek Drive, Durham, CA, US, 27703

Stock Price USD

Price Change

Last Dividend USD

NOVN's stock peer is ACST (Acasti Pharma Inc.)

NOVN's stock peer is ADIL (Adial Pharmaceuticals, Inc.)

NOVN's stock peer is ADTX (Aditxt, Inc.)

NOVN's stock peer is AEZS (Aeterna Zentaris Inc.)

NOVN's stock peer is ALDX (Aldeyra Therapeutics, Inc.)

NOVN's stock peer is DFFN (Diffusion Pharmaceuticals Inc.)

NOVN's stock peer is ETON (Eton Pharmaceuticals, Inc.)

NOVN's stock peer is JAGX (Jaguar Health, Inc.)

NOVN's stock peer is LYRA (Lyra Therapeutics, Inc.)

NOVN's stock peer is ONTX (Onconova Therapeutics, Inc.)

NOVN's stock peer is PALI (Palisade Bio, Inc.)

NOVN's stock peer is PSTV (Plus Therapeutics, Inc.)

NOVN's stock peer is QNRX (Quoin Pharmaceuticals, Ltd.)

NOVN's stock peer is REVB (Revelation Biosciences, Inc.)

NOVN's stock peer is SQZ (SQZ Biotechnologies Company)

NOVN's stock peer is TARA (Protara Therapeutics, Inc.)

NOVN's stock peer is TARS (Tarsus Pharmaceuticals, Inc.)

NOVN's stock peer is TCON (TRACON Pharmaceuticals, Inc.)

NOVN's stock peer is TNXP (Tonix Pharmaceuticals Holding Corp.)

NOVN's stock peer is TRVI (Trevi Therapeutics, Inc.)

NOVN's stock peer is TVTX (Travere Therapeutics, Inc.)

Healthcare Biotechnology

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions